Abstract 1792
Background
Prostate cancer (PC) is the second most common type of cancer among men. During radiotherapy (RT), some of the healthy tissues can be irradiated and side effects such as urinary (UI) and fecal incontinence (FI) may occur.
Methods
This non-randomized study was conducted to determine the effect of Kegel exercises on prevention of UI and FI in PC patients undergoing RT at the Gazi Hospital in the dates of 10.12.2016-03.01.2018. 60 patients were included in the study, 30 in the experimental and 30 in the control group. Data was collected with information form, CTCAE, EORTC QLQ-C30, REALM, weekly exercise follow-up schedule. The experimental group was provided individual training on Kegel exercises, training booklet was given, and patients were followed up weekly. Data collection forms were repeated before training, at the end of the first month and second month. No similar intervention was provided for the control group. Chi-square, Mann-Whitney U, Kruskal-Wallis, Friedman, Wilcoxon tests, variance analysis were used for the data analysis.
Results
Experimental and control groups were found to have been distributed homogeneously. At the end of first month, 10% of the experimental group and 13.3% of the control group had first grade UI. At the end of second month, only 1% of the control group had first grade UI, 3.3% of the experimental group and 6,7% of the control group had second grade UI. Besides, FI was not developed in both groups. It was found that social function of the EORTC QLQ-C30 increased in the experimental group. Additionally, diarrhea, insomnia, loss of appetite in the symptom sub-scale decreased in the same group. Improvement was observed in the overall health condition of the experimental group, whereas the control group was observed to be worse (p < 0,05).
Conclusions
Although Kegel exercises were not found effective, UI rate was lower in the experimental group. It has been recommended that Kegel exercises should be performed in larger groups with long-term observations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Aydan Eda Urvaylıoğlu, Sevinç Kutlutürkan, Diclehan Kılıç.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract